Ligand to spin off J&J-partnered antibody unit with $70M in fundingnews2022-02-18T14:35:24+00:00February 18th, 2022|FierceBiotech|
FDA grounds BioMarin gene therapy trial for months with demand for tumor risk datanews2022-02-18T11:13:33+00:00February 18th, 2022|FierceBiotech|
GSK, in close race with Pfizer, slams brakes on phase 3 maternal RSV vaccine program over safety signalnews2022-02-18T10:04:36+00:00February 18th, 2022|FierceBiotech|
‘Early stage’: Majority of biotechs don’t disclose ESG practices, but most plan to in near termnews2022-02-17T16:23:34+00:00February 17th, 2022|FierceBiotech|
After clinical hold, Yumanity to cut 60% of workforce by April and hunt for a buyernews2022-02-17T15:56:03+00:00February 17th, 2022|FierceBiotech|
Recommended Strategies for Your Next Biomarker-Driven Clinical Trialnews2022-02-17T14:40:34+00:00February 17th, 2022|FierceBiotech|
Ex-NIH chief Collins returns as science adviser to Biden weeks into retirementnews2022-02-17T14:35:04+00:00February 17th, 2022|FierceBiotech|
Innovent’s phase 3 hits tee it up to challenge Amgen and Sanofi for Chinese PCSK9 marketnews2022-02-17T14:14:37+00:00February 17th, 2022|FierceBiotech|
Billionaire’s fund backs Heidelberg to carve out niche in busy BCMA spacenews2022-02-17T12:56:24+00:00February 17th, 2022|FierceBiotech|
Remix Therapeutics signs Janssen licensing deal that could top $1Bnews2022-02-16T23:00:34+00:00February 16th, 2022|FierceBiotech|
